Credit Suisse International Form 8.5 (EPT/RI) - Mediclinic International plc (6994A)
2023年5月25日 - 10:39PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMMDC
RNS Number : 6994A
Credit Suisse International
25 May 2023
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH
RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader: Credit Suisse International
(b) Name of offeror/offeree in relation Mediclinic International PLC
to whose relevant securities this
form relates: Use a separate form
for each offeror/offeree
---------------------------------------
(c) Name of the party to the offer A consortium comprising Remgro Limited
with which exempt principal trader and MSC Mediterranean Shipping Company
is connected: SA (acting through its wholly owned
subsidiary SAS Shipping Agencies
Services Sarl)
---------------------------------------
(d) Date dealing undertaken: 24-May-2023
---------------------------------------
(e) In addition to the company in N/A
1(b) above, is the exempt principal If YES, specify which:
trader making disclosures in respect
of any other party to this offer?
If it is a cash offer or possible
cash offer, state "N/A"
---------------------------------------
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(b), copy
table 2(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
Class of relevant Purchases/ Total number Highest price per Lowest price per
security sales of securities unit paid/received unit paid/received
GBp 10 ordinary Purchase 200 5.00 GBP 5.00 GBP
---------- -------------- ------------------- -------------------
GBp 10 ordinary Sale 200 5.00 GBP 5.00 GBP
---------- -------------- ------------------- -------------------
(b) Cash-settled derivative transactions
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing securities
a long/short position,
increasing/reducing
a long/short position
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class Product description Writing, Number Exercise price Type e.g. Expiry Option money
of relevant e.g. call option purchasing, of securities per unit American, date paid/ received
security selling, to which European per unit
varying option etc.
etc. relates
(ii) Exercise
Class of relevant Product description Exercising/ Number of securities Exercise price
security e.g. call option exercised per unit
against
(d) Other dealings (including subscribing for new securities)
Class of relevant Nature of dealing Details Price per unit
security e.g. subscription, (if applicable)
conversion
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities
which may be an inducement to deal or refrain from dealing entered
into by the exempt principal trader making the disclosure and any party
to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included.
If there are no such agreements, arrangements or understandings, state
"none"
none
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or
informal, between the exempt principal trader making the disclosure
and any other person relating to: (i) the voting rights of any relevant
securities under any option; or (ii) the voting rights or future acquisition
or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state
"none"
none
Date of disclosure: 25-May-2023
Contact name: Anthony Allen / Paul MacDonald
------------------------------
Telephone number: 0207 888 5416 / 8548
------------------------------
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for
consultation in relation to the Code's dealing disclosure
requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FERBXGDUIXDDGXU
(END) Dow Jones Newswires
May 25, 2023 09:39 ET (13:39 GMT)
Mediclinic (LSE:MDC)
過去 株価チャート
から 11 2024 まで 12 2024
Mediclinic (LSE:MDC)
過去 株価チャート
から 12 2023 まで 12 2024
